Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024
Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has announced that it will release its third quarter 2024 financial results after the close of trading on Wednesday, October 30, 2024. The company management will host a conference call to discuss the financial results, starting at 1:30 p.m. PT / 4:30 p.m. ET on the same day.
Investors and interested parties can access a live and archived webcast of the event on the 'Investors' section of the Pulmonx website at https://investors.pulmonx.com/. This announcement provides an opportunity for stakeholders to gain insights into the company's financial performance and future outlook.
Pulmonx (Nasdaq: LUNG), un leader globale nei trattamenti minimamente invasivi per le malattie polmonari, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 dopo la chiusura delle contrattazioni il mercoledì 30 ottobre 2024. La direzione dell'azienda ospiterà una conferenza telefonica per discutere i risultati finanziari, che avrà inizio alle 1:30 p.m. PT / 4:30 p.m. ET dello stesso giorno.
Gli investitori e le parti interessate possono accedere a una diretta e a una registrazione dell'evento nella sezione 'Investitori' del sito web di Pulmonx all'indirizzo https://investors.pulmonx.com/. Questo annuncio offre un'opportunità ai portatori di interesse per ottenere informazioni sulle performance finanziarie dell'azienda e sulle prospettive future.
Pulmonx (Nasdaq: LUNG), un líder global en tratamientos mínimamente invasivos para enfermedades pulmonares, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 después del cierre de la negociación el miércoles 30 de octubre de 2024. La dirección de la empresa llevará a cabo una llamada de conferencia para discutir los resultados financieros, que comenzará a las 1:30 p.m. PT / 4:30 p.m. ET del mismo día.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo y grabada del evento en la sección 'Inversores' del sitio web de Pulmonx en https://investors.pulmonx.com/. Este anuncio ofrece una oportunidad para que los interesados obtengan información sobre el rendimiento financiero de la empresa y sus perspectivas futuras.
Pulmonx (Nasdaq: LUNG)는 폐 질환을 위한 최소 침습 치료의 글로벌 선두주자로, 2024년 3분기 재무 결과를 2024년 10월 30일 수요일 거래 종료 후 발표할 것이라고 발표했습니다. 회사 경영진은 같은 날 오후 1시 30분 PT / 오후 4시 30분 ET에 재무 결과를 논의하기 위해 컨퍼런스 콜을 개최할 예정입니다.
투자자 및 이해관계자는 Pulmonx 웹사이트의 '투자자' 섹션에서 이벤트의 생중계 및 아카이브된 웹캐스트에 접근할 수 있습니다: https://investors.pulmonx.com/. 이 발표는 이해관계자들이 회사의 재무 성과와 향후 전망에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Pulmonx (Nasdaq: LUNG), un leader mondial dans les traitements mini-invasifs pour les maladies pulmonaires, a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 après la clôture des marchés le mercredi 30 octobre 2024. La direction de l'entreprise tiendra une conférence téléphonique pour discuter des résultats financiers, débutant à 13h30 PT / 16h30 ET le même jour.
Les investisseurs et les parties intéressées peuvent accéder à une diffusion en direct ainsi qu'à un enregistrement de l'événement dans la section 'Investisseurs' du site web de Pulmonx à l'adresse https://investors.pulmonx.com/. Cet annonce offre une occasion aux parties prenantes d'obtenir des informations sur la performance financière de l'entreprise et ses perspectives d'avenir.
Pulmonx (Nasdaq: LUNG), ein globaler Marktführer in minimalinvasiven Behandlungen von Lungenerkrankungen, hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 nach Börsenschluss am Mittwoch, den 30. Oktober 2024 veröffentlichen wird. Das Management des Unternehmens wird am selben Tag um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Finanzergebnisse zu besprechen.
Investoren und interessierte Parteien können eine Live-Übertragung und ein Archiv des Ereignisses im Bereich 'Investoren' auf der Pulmonx-Website unter https://investors.pulmonx.com/ abrufen. Diese Ankündigung bietet den Stakeholdern die Möglichkeit, Einblicke in die finanzielle Performance des Unternehmens und die zukünftigen Aussichten zu gewinnen.
- None.
- None.
REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Wednesday, October 30, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
When will Pulmonx (LUNG) release its Q3 2024 financial results?
What time is the Pulmonx (LUNG) Q3 2024 earnings conference call?
Where can I access the webcast for Pulmonx's (LUNG) Q3 2024 earnings call?
What does Pulmonx (LUNG) specialize in?
